Alkermes plc Ordinary Shares Share Price
NASDAQ: ALKS | Mid CapAlkermes plc Ordinary Shares Stock Performance
Open $49.73 | Prev. Close $49.71 | Circuit Range N/A |
Day Range $48.24 - $49.90 | Year Range $25.16 - $55.60 | Volume 86,401 |
Average Traded $48.67 |
Alkermes plc Ordinary Shares Share Price Today
As of 8 August 2026, Alkermes plc Ordinary Shares's share price is $48.41. The stock opened at $49.73, compared to its previous close of $49.71. During today's trading session, Alkermes plc Ordinary Shares's share price traded between $48.24 and $49.90, with an average price of $49.07. Over the past 52 weeks, the stock has recorded a high of $55.60 and a low of $25.16. In terms of performance, Alkermes plc Ordinary Shares's share price has risen by 60.94% over the last six months and is up 67.16% on a year-on-year basis.
Alkermes plc Ordinary Shares Share Price Chart
Alkermes plc Ordinary Shares Stock Fundamentals & Key Indicators
Market Cap $7.97B | PE Ratio (TTM) 32.93 | Dividend Yield N/A |
EPS (TTM) $1.47 | Revenue (TTM) $1.48B | Return On Equity (TTM) 13.28% |
Profit Margin 16.37% | Debt to Equity 0.30 | Quarterly Earnings Growth YoY -10.41% |
Alkermes plc Ordinary Shares Quarterly Profit & Loss
All figures in USD
Alkermes plc Ordinary Shares Annual Profit & Loss
All figures in USD
About Alkermes plc Ordinary Shares
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc Ordinary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $49.08 | $48.37 | -1.26% |
Jul 2026 | $52.27 | $48.98 | -6.51% |
Jun 2026 | $42.09 | $52.39 | +24.19% |
May 2026 | $33.22 | $42.19 | +25.10% |
Apr 2026 | $35.81 | $33.72 | -4.69% |
Mar 2026 | $29.69 | $35.38 | +17.62% |
Feb 2026 | $33.52 | $30.08 | -11.22% |
Jan 2026 | $28.16 | $33.88 | +21.13% |
Dec 2025 | $29.25 | $27.97 | -5.38% |
Nov 2025 | $30.43 | $29.56 | -3.71% |
Oct 2025 | $29.98 | $30.70 | +2.33% |
Sep 2025 | $29.16 | $30.00 | +3.59% |
ALKS Share Price FAQs
What is Alkermes plc Ordinary Shares share price today?
What is the 52 week high and 52 week low of Alkermes plc Ordinary Shares stock?
What is ALKS's market capitalisation today?
What is ALKS's net income for the last quarter?
What is the 5 year returns of ALKS?
What is the high & low stock price of ALKS today?
Can I buy ALKS shares in India?